China Resources Pharmaceutical Group Limited’s (CHINARES PHARMA, 03320) controlled subsidiary Dong-E-E-Jiao Company Limited released unaudited results for the nine months ended 30 September 2026, showing modest top- and bottom-line growth despite a sharp swing in cash flow and a leaner balance sheet.

1. Operating Performance • Revenue reached RMB4.94 billion, up 3.6% from RMB4.77 billion in the prior-year period. • Net profit increased 4.0% year on year to RMB1.33 billion, compared with RMB1.28 billion a year earlier. • The profit uplift marginally outpaced sales growth, pointing to stable margins in the period under review.

2. Cash Flow and Liquidity • Net cash and cash equivalents fell by RMB0.76 billion, versus an inflow of RMB0.51 billion in the comparable period last year, signalling heavier cash outlays or working-capital absorption. • Period-end cash and cash equivalents stood at RMB2.64 billion, down 18.4% from RMB3.24 billion as at 30 September 2025.

3. Balance-Sheet Snapshot (30 September 2026 vs. 31 December 2025) • Total assets decreased 7.2% to RMB12.42 billion. • Total liabilities contracted 15.2% to RMB2.56 billion, indicating reduced leverage. • Owner’s equity slipped 4.8% to RMB9.87 billion.

4. Ownership Structure • CHINARES PHARMA directly holds 10.26% of Dong-E-E-Jiao and, through its non-wholly-owned subsidiary China Resources Dong-E-E-Jiao Company Limited, effectively controls 23.66% of the A-share listed firm. • Dong-E-E-Jiao remains consolidated as a subsidiary in CHINARES PHARMA’s financial statements.

5. Reporting Status The disclosed figures are prepared under PRC GAAP and remain unaudited; adjustments may arise upon completion of the statutory audit. Investors are advised to consider these preliminary results within the broader context of CHINARES PHARMA’s consolidated performance.

Further details are available in Dong-E-E-Jiao’s full quarterly report filed with the Shenzhen Stock Exchange on 23 October 2026.